Exclusive US FDA delays two drug reviews in new voucher program after safety, efficacy concerns
Jan 15 (Reuters) - The U.S. Food and Drug Administration has delayed reviews of two drugs chosen for the Trump administration's new fast-track program after agency scientists flagged safety and efficacy concerns, including the death of a patient while...
Reuters